MedTrace Logo

Lu AF28996 in Participants With Parkinson's Disease (PD)

NCT04291859 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2026-03-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Lu AF28996

capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-26
Primary Completion
2025-10-14
Completion
2026-02-12
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Netherlands
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04291859 on ClinicalTrials.gov